Healthcare / Medical Instruments & SuppliesHKSE
$1.18
+0.01 (+0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $135.7M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
16.9x
↓EV/EBITDA
0.0x
↓ROE
2.4%
↑Gross Margin
49.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.3%
FCF CAGR
-13.2%
FCF margin
16.5%
FCF / Net income
1.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $823.5M · net income $94.4M · FCF $135.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $823.5M | $823.5M | $768.9M | $675.1M | $536.8M |
| Net Income | $94.4M | $94.4M | $150.8M | $153.2M | $106.0M |
| EBITDA | $305.6M | $305.6M | $347.9M | $329.5M | $236.8M |
| EPS | 0.06 | 0.06 | 0.10 | 0.10 | 0.07 |
| Gross Margin | 49.5% | 49.5% | 54.6% | 56.4% | 55.7% |
| Operating Margin | 12.2% | 12.2% | 18.1% | 24.1% | 12.7% |
| Net Margin | 11.5% | 11.5% | 19.6% | 22.7% | 19.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 10.89 | 10.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $135.7M | $135.7M | $246.3M | $129.1M | $207.4M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 3.8% | 3.8% | 2.7% |
| Valuation | |||||
| P/E | 16.86 | 16.86 | 10.03 | 8.59 | 9.01 |
| EV/EBITDA | 0.01 | 0.01 | -0.45 | -0.83 | -1.78 |
| P/B | 0.45 | 0.45 | 0.38 | 0.33 | 0.24 |
| Growth & Yield | |||||
| Revenue Growth | 7.1% | 7.1% | 13.9% | 25.8% | — |
| EPS Growth | -36.0% | -36.0% | -0.1% | 44.5% | — |
| Dividend Yield | 5.5% | 5.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.8%
EPS terminal req.
$0.10
Spread vs growth
-54.8%
5Y implied EPS CAGR
15.2%
EPS terminal req.
$0.13
Spread vs growth
-51.2%
10Y implied EPS CAGR
12.6%
EPS terminal req.
$0.20
Spread vs growth
-48.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+18.9%
Start / end P/E
10.6x → 18.9x
EPS bridge
0.10 → 0.06
Residual
-27.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.